Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
| Revenue (TTM) | $3.98B |
| Gross Profit (TTM) | $1.40B |
| EBITDA | $909.38M |
| Operating Margin | 23.40% |
| Return on Equity | 1.27% |
| Return on Assets | 4.74% |
| Revenue/Share (TTM) | $82.00 |
| Book Value | $67.40 |
| Price-to-Book | 4.65 |
| Price-to-Sales (TTM) | 4.07 |
| EV/Revenue | 4.438 |
| EV/EBITDA | 60.00 |
| Quarterly Earnings Growth (YoY) | 524.00% |
| Quarterly Revenue Growth (YoY) | -2.20% |
| Shares Outstanding | $47.92M |
| Float | $47.40M |
| % Insiders | 0.47% |
| % Institutions | 117.17% |
Volatility is currently expanding
Charles River Laboratories International NYSE: CRL raised its 2026 revenue and earnings outlook after third-quarter organic revenue growth accelerated to 4.7%, supported by demand for safety assessment and manufacturing testing services.
Charles River Laboratories International, Inc. (CRL) Q3 2026 Earnings Call Transcript
CRL beats Q3 earnings and revenue estimates as organic growth and margin expansion drive results, prompting the company to raise its 2026 outlook.
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Charles River Laboratories (CRL) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.43 per share a year ago.
CRL's Q3'26 results face pressure from declining segment revenues, but improving biopharma demand and strength in Microbial Solutions could provide support.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.
ZBRA's revenue growth accelerated across end markets and geographies, while margins and earnings exceeded expectations. CRL's results reflected improving demand across biopharma and biotechnology customers. Bio-Rad's shares also benefited from the announcement of a broad restructuring program designed to streamline operations and enhance profitability.
Investors interested in Medical Services stocks are likely familiar with Progyny (PGNY) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
CRL shares have surged 75.8% in a year as RMS trends improve, AI-enabled testing expands and cash flow supports buybacks and investment.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRL and any ticker you trade — then tracks every position and per-strategy win rate.
